Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Breast Neoplasms | 39 | 2018 | 765 | 3.790 |
Why?
|
Gene Expression Profiling | 37 | 2020 | 322 | 2.740 |
Why?
|
Gene Expression Regulation, Neoplastic | 31 | 2018 | 261 | 2.340 |
Why?
|
Oligonucleotide Array Sequence Analysis | 23 | 2016 | 160 | 1.310 |
Why?
|
Appendiceal Neoplasms | 3 | 2020 | 98 | 1.280 |
Why?
|
Neoplasms | 6 | 2020 | 726 | 1.110 |
Why?
|
Prognosis | 25 | 2020 | 1495 | 1.090 |
Why?
|
Immunotherapy | 6 | 2020 | 81 | 0.990 |
Why?
|
Peritoneal Neoplasms | 3 | 2020 | 259 | 0.850 |
Why?
|
Humans | 87 | 2020 | 31974 | 0.800 |
Why?
|
Evolution, Molecular | 2 | 2016 | 34 | 0.800 |
Why?
|
Lung Neoplasms | 6 | 2019 | 412 | 0.740 |
Why?
|
Female | 56 | 2020 | 19939 | 0.710 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2020 | 91 | 0.660 |
Why?
|
Iron | 5 | 2017 | 116 | 0.640 |
Why?
|
Cell Line, Tumor | 29 | 2018 | 726 | 0.640 |
Why?
|
Receptors, Estrogen | 12 | 2018 | 113 | 0.640 |
Why?
|
Cell Proliferation | 13 | 2018 | 604 | 0.620 |
Why?
|
Cluster Analysis | 10 | 2016 | 125 | 0.590 |
Why?
|
Immunity | 2 | 2016 | 22 | 0.570 |
Why?
|
Brain Neoplasms | 6 | 2019 | 638 | 0.570 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 3 | 2019 | 101 | 0.550 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 5 | 2020 | 458 | 0.540 |
Why?
|
Cancer Vaccines | 1 | 2015 | 24 | 0.520 |
Why?
|
Computational Biology | 8 | 2020 | 91 | 0.510 |
Why?
|
Genomics | 5 | 2018 | 85 | 0.490 |
Why?
|
Mice | 17 | 2020 | 2484 | 0.460 |
Why?
|
Tumor Suppressor Protein p53 | 4 | 2017 | 82 | 0.460 |
Why?
|
Oncogenes | 3 | 2020 | 13 | 0.450 |
Why?
|
Genes, Immunoglobulin | 1 | 2013 | 4 | 0.450 |
Why?
|
Major Histocompatibility Complex | 1 | 2013 | 16 | 0.440 |
Why?
|
Mutation | 5 | 2017 | 489 | 0.440 |
Why?
|
Animals | 24 | 2020 | 7541 | 0.410 |
Why?
|
Transcription, Genetic | 8 | 2010 | 137 | 0.400 |
Why?
|
Algorithms | 8 | 2015 | 492 | 0.400 |
Why?
|
Transcription Factors | 5 | 2013 | 181 | 0.390 |
Why?
|
Neoplasm Staging | 7 | 2018 | 447 | 0.380 |
Why?
|
Middle Aged | 22 | 2020 | 11804 | 0.370 |
Why?
|
Tamoxifen | 7 | 2015 | 59 | 0.360 |
Why?
|
Glioblastoma | 3 | 2018 | 156 | 0.360 |
Why?
|
Genes, ras | 1 | 2009 | 26 | 0.340 |
Why?
|
YY1 Transcription Factor | 3 | 2016 | 6 | 0.340 |
Why?
|
Adaptor Proteins, Signal Transducing | 1 | 2009 | 67 | 0.330 |
Why?
|
Carcinoma, Hepatocellular | 3 | 2019 | 60 | 0.330 |
Why?
|
Proportional Hazards Models | 4 | 2020 | 753 | 0.320 |
Why?
|
Membrane Proteins | 2 | 2009 | 256 | 0.320 |
Why?
|
Melanoma | 3 | 2019 | 164 | 0.320 |
Why?
|
Adenocarcinoma | 5 | 2019 | 308 | 0.320 |
Why?
|
Adult | 15 | 2020 | 9339 | 0.310 |
Why?
|
Gene Expression Regulation | 5 | 2016 | 495 | 0.310 |
Why?
|
Liver Neoplasms | 3 | 2019 | 155 | 0.300 |
Why?
|
Mice, Inbred BALB C | 4 | 2020 | 167 | 0.300 |
Why?
|
SARS Virus | 2 | 2004 | 7 | 0.300 |
Why?
|
Survival Rate | 6 | 2020 | 877 | 0.290 |
Why?
|
Estrogen Receptor alpha | 4 | 2016 | 52 | 0.290 |
Why?
|
DNA, Bacterial | 1 | 2007 | 27 | 0.290 |
Why?
|
Treatment Outcome | 12 | 2019 | 3302 | 0.290 |
Why?
|
Signal Transduction | 8 | 2019 | 682 | 0.280 |
Why?
|
Antigens, Neoplasm | 3 | 2019 | 45 | 0.280 |
Why?
|
Neoplasm Invasiveness | 9 | 2016 | 190 | 0.280 |
Why?
|
Receptor, erbB-2 | 2 | 2018 | 65 | 0.280 |
Why?
|
Organ Specificity | 2 | 2019 | 81 | 0.280 |
Why?
|
Bacteria | 1 | 2007 | 48 | 0.270 |
Why?
|
Cell Line | 4 | 2020 | 435 | 0.270 |
Why?
|
Systems Biology | 1 | 2006 | 10 | 0.270 |
Why?
|
Leukocytes | 2 | 2016 | 57 | 0.270 |
Why?
|
Male | 22 | 2020 | 19143 | 0.270 |
Why?
|
Drug Resistance, Neoplasm | 5 | 2018 | 104 | 0.260 |
Why?
|
Predictive Value of Tests | 5 | 2015 | 873 | 0.260 |
Why?
|
Models, Biological | 4 | 2019 | 392 | 0.260 |
Why?
|
Aged | 16 | 2020 | 10294 | 0.260 |
Why?
|
Genetic Markers | 2 | 2015 | 124 | 0.260 |
Why?
|
Genome, Human | 6 | 2011 | 132 | 0.260 |
Why?
|
Antineoplastic Agents, Hormonal | 4 | 2015 | 42 | 0.260 |
Why?
|
Gene Expression | 7 | 2018 | 338 | 0.250 |
Why?
|
Models, Genetic | 4 | 2011 | 94 | 0.250 |
Why?
|
Gene Regulatory Networks | 2 | 2020 | 41 | 0.250 |
Why?
|
Thyroid Hormone Resistance Syndrome | 1 | 2004 | 1 | 0.240 |
Why?
|
RNA, Small Interfering | 9 | 2019 | 114 | 0.240 |
Why?
|
Coronavirus | 1 | 2004 | 3 | 0.240 |
Why?
|
Disease Progression | 6 | 2018 | 593 | 0.230 |
Why?
|
Cohort Studies | 6 | 2018 | 1813 | 0.230 |
Why?
|
Antibodies, Monoclonal | 2 | 2015 | 246 | 0.220 |
Why?
|
Ovarian Neoplasms | 2 | 2017 | 96 | 0.220 |
Why?
|
Software | 4 | 2008 | 123 | 0.210 |
Why?
|
Tumor Suppressor Proteins | 3 | 2015 | 71 | 0.210 |
Why?
|
Neoplasm Proteins | 3 | 2016 | 148 | 0.210 |
Why?
|
Estrogen Receptor Modulators | 3 | 2012 | 25 | 0.210 |
Why?
|
Disease Models, Animal | 2 | 2019 | 1022 | 0.210 |
Why?
|
Proteins | 2 | 2015 | 144 | 0.200 |
Why?
|
Disease-Free Survival | 6 | 2014 | 317 | 0.200 |
Why?
|
Bone Morphogenetic Protein 7 | 2 | 2020 | 18 | 0.200 |
Why?
|
Polymerase Chain Reaction | 4 | 2016 | 198 | 0.200 |
Why?
|
Prostatic Neoplasms | 2 | 2018 | 471 | 0.200 |
Why?
|
Immunohistochemistry | 6 | 2016 | 538 | 0.200 |
Why?
|
Sulfides | 3 | 2018 | 26 | 0.190 |
Why?
|
Caprylates | 3 | 2018 | 27 | 0.190 |
Why?
|
Lymphatic Metastasis | 3 | 2011 | 166 | 0.180 |
Why?
|
Survival Analysis | 5 | 2018 | 482 | 0.180 |
Why?
|
DNA-Binding Proteins | 2 | 2013 | 147 | 0.180 |
Why?
|
Co-Repressor Proteins | 1 | 2020 | 3 | 0.180 |
Why?
|
Syndecan-1 | 1 | 2019 | 11 | 0.170 |
Why?
|
Neoplasm Metastasis | 3 | 2016 | 220 | 0.170 |
Why?
|
Adenocarcinoma, Mucinous | 1 | 2020 | 29 | 0.170 |
Why?
|
Plasma Cells | 1 | 2019 | 11 | 0.170 |
Why?
|
Drug Screening Assays, Antitumor | 1 | 2019 | 58 | 0.170 |
Why?
|
Promoter Regions, Genetic | 5 | 2013 | 208 | 0.170 |
Why?
|
Immunologic Factors | 1 | 2020 | 49 | 0.170 |
Why?
|
Leukocytes, Mononuclear | 1 | 2019 | 56 | 0.170 |
Why?
|
DNA Primers | 4 | 2008 | 91 | 0.170 |
Why?
|
Microarray Analysis | 3 | 2010 | 19 | 0.170 |
Why?
|
DNA | 5 | 2011 | 226 | 0.170 |
Why?
|
Phenotype | 2 | 2016 | 632 | 0.170 |
Why?
|
Antigens, Nuclear | 1 | 2019 | 7 | 0.170 |
Why?
|
Nuclear Matrix-Associated Proteins | 1 | 2019 | 5 | 0.170 |
Why?
|
Magnetic Field Therapy | 1 | 2019 | 17 | 0.170 |
Why?
|
DNA Breaks, Double-Stranded | 1 | 2019 | 17 | 0.170 |
Why?
|
Gene Dosage | 2 | 2009 | 35 | 0.170 |
Why?
|
Cystatin A | 1 | 2019 | 8 | 0.170 |
Why?
|
Reproducibility of Results | 5 | 2011 | 762 | 0.170 |
Why?
|
RNA Interference | 4 | 2016 | 76 | 0.160 |
Why?
|
Interleukin-23 Subunit p19 | 1 | 2019 | 11 | 0.160 |
Why?
|
Calcium Channels, T-Type | 1 | 2019 | 29 | 0.160 |
Why?
|
Myeloid Cells | 1 | 2019 | 39 | 0.160 |
Why?
|
Mice, Nude | 7 | 2013 | 291 | 0.160 |
Why?
|
Carcinoma, Bronchogenic | 1 | 2018 | 7 | 0.160 |
Why?
|
RNA, Neoplasm | 1 | 2018 | 20 | 0.160 |
Why?
|
DNA Repair | 1 | 2019 | 64 | 0.160 |
Why?
|
Chemotherapy, Cancer, Regional Perfusion | 1 | 2020 | 155 | 0.160 |
Why?
|
Organoids | 1 | 2019 | 94 | 0.160 |
Why?
|
Combined Modality Therapy | 1 | 2020 | 560 | 0.160 |
Why?
|
NAD | 1 | 2018 | 27 | 0.160 |
Why?
|
Biopsy, Fine-Needle | 1 | 2018 | 53 | 0.160 |
Why?
|
Membrane Glycoproteins | 1 | 2018 | 101 | 0.150 |
Why?
|
SEER Program | 1 | 2018 | 30 | 0.150 |
Why?
|
Esophageal Neoplasms | 2 | 2008 | 35 | 0.150 |
Why?
|
DNA, Viral | 3 | 2008 | 54 | 0.150 |
Why?
|
Neoplastic Stem Cells | 3 | 2019 | 99 | 0.150 |
Why?
|
Hematologic Diseases | 1 | 2017 | 23 | 0.140 |
Why?
|
Calcium | 1 | 2019 | 307 | 0.140 |
Why?
|
Down-Regulation | 6 | 2019 | 142 | 0.140 |
Why?
|
Sequence Analysis, DNA | 4 | 2017 | 137 | 0.140 |
Why?
|
Retrospective Studies | 3 | 2020 | 3502 | 0.140 |
Why?
|
Mitochondrial Diseases | 1 | 2016 | 11 | 0.140 |
Why?
|
Recurrence | 3 | 2019 | 263 | 0.140 |
Why?
|
Estradiol | 4 | 2010 | 136 | 0.140 |
Why?
|
Nerve Sheath Neoplasms | 1 | 2016 | 8 | 0.140 |
Why?
|
Neoplasms, Squamous Cell | 1 | 2016 | 9 | 0.140 |
Why?
|
DNA Methylation | 6 | 2015 | 140 | 0.140 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2016 | 9 | 0.140 |
Why?
|
Chromosome Mapping | 2 | 2008 | 193 | 0.140 |
Why?
|
Peptides | 3 | 2016 | 120 | 0.140 |
Why?
|
Zebrafish | 2 | 2006 | 23 | 0.140 |
Why?
|
Phosphorylation | 3 | 2016 | 229 | 0.140 |
Why?
|
Sexual Maturation | 1 | 2016 | 25 | 0.130 |
Why?
|
Immunomodulation | 1 | 2016 | 32 | 0.130 |
Why?
|
Th1 Cells | 1 | 2016 | 25 | 0.130 |
Why?
|
Multiprotein Complexes | 1 | 2016 | 18 | 0.130 |
Why?
|
Radiosurgery | 1 | 2019 | 356 | 0.130 |
Why?
|
Mammary Glands, Animal | 1 | 2016 | 65 | 0.130 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2016 | 70 | 0.130 |
Why?
|
Pancreatic Neoplasms | 1 | 2017 | 134 | 0.130 |
Why?
|
Soybean Proteins | 1 | 2016 | 74 | 0.130 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 2018 | 201 | 0.130 |
Why?
|
Receptors, Progesterone | 3 | 2018 | 72 | 0.130 |
Why?
|
Colorectal Neoplasms | 1 | 2017 | 215 | 0.120 |
Why?
|
Carboplatin | 1 | 2015 | 48 | 0.120 |
Why?
|
Epithelial Cells | 5 | 2016 | 141 | 0.120 |
Why?
|
Carrier Proteins | 2 | 2016 | 136 | 0.120 |
Why?
|
DEAD Box Protein 20 | 1 | 2014 | 1 | 0.120 |
Why?
|
Paclitaxel | 1 | 2015 | 67 | 0.120 |
Why?
|
Transplantation, Heterologous | 5 | 2013 | 122 | 0.120 |
Why?
|
Apolipoproteins | 1 | 2016 | 200 | 0.120 |
Why?
|
Urinary Bladder Neoplasms | 1 | 2017 | 192 | 0.120 |
Why?
|
Severe Acute Respiratory Syndrome | 2 | 2004 | 10 | 0.120 |
Why?
|
Lipoproteins, HDL | 1 | 2016 | 251 | 0.120 |
Why?
|
Chemotherapy, Adjuvant | 2 | 2012 | 190 | 0.120 |
Why?
|
Hematologic Neoplasms | 1 | 2014 | 35 | 0.120 |
Why?
|
Iron Regulatory Protein 2 | 1 | 2013 | 2 | 0.120 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 6 | 2011 | 263 | 0.120 |
Why?
|
Cell Movement | 5 | 2014 | 169 | 0.120 |
Why?
|
Kidney Diseases | 1 | 2016 | 249 | 0.110 |
Why?
|
SOXF Transcription Factors | 1 | 2013 | 4 | 0.110 |
Why?
|
Skin Neoplasms | 1 | 2016 | 214 | 0.110 |
Why?
|
NF-kappa B | 2 | 2014 | 81 | 0.110 |
Why?
|
Estrogen Antagonists | 2 | 2010 | 17 | 0.110 |
Why?
|
Epigenesis, Genetic | 2 | 2015 | 104 | 0.110 |
Why?
|
Tumor Suppressor Protein p14ARF | 1 | 2012 | 1 | 0.110 |
Why?
|
Cell Transformation, Neoplastic | 2 | 2012 | 57 | 0.110 |
Why?
|
Proto-Oncogene Proteins c-mdm2 | 1 | 2012 | 8 | 0.110 |
Why?
|
Jumonji Domain-Containing Histone Demethylases | 1 | 2012 | 1 | 0.100 |
Why?
|
Transforming Growth Factor beta2 | 1 | 2012 | 6 | 0.100 |
Why?
|
Cyclin-Dependent Kinase 2 | 1 | 2012 | 4 | 0.100 |
Why?
|
Cyclins | 1 | 2012 | 6 | 0.100 |
Why?
|
Carcinoma, Squamous Cell | 2 | 2019 | 154 | 0.100 |
Why?
|
Y-Box-Binding Protein 1 | 1 | 2011 | 1 | 0.100 |
Why?
|
Proliferating Cell Nuclear Antigen | 1 | 2012 | 31 | 0.100 |
Why?
|
E2F1 Transcription Factor | 1 | 2011 | 3 | 0.100 |
Why?
|
Protein Array Analysis | 1 | 2011 | 15 | 0.100 |
Why?
|
Recombinases | 1 | 2011 | 2 | 0.100 |
Why?
|
5' Untranslated Regions | 1 | 2011 | 5 | 0.100 |
Why?
|
G-Quadruplexes | 1 | 2011 | 8 | 0.100 |
Why?
|
DEAD-box RNA Helicases | 1 | 2011 | 9 | 0.100 |
Why?
|
Gene Silencing | 1 | 2011 | 48 | 0.100 |
Why?
|
Neoplasms, Hormone-Dependent | 1 | 2011 | 9 | 0.100 |
Why?
|
Transfection | 4 | 2018 | 191 | 0.100 |
Why?
|
Genes, Tumor Suppressor | 2 | 2008 | 34 | 0.100 |
Why?
|
Mitochondria | 3 | 2018 | 187 | 0.100 |
Why?
|
Sensitivity and Specificity | 3 | 2008 | 582 | 0.090 |
Why?
|
Gene Knockdown Techniques | 3 | 2019 | 77 | 0.090 |
Why?
|
Smad Proteins | 1 | 2010 | 7 | 0.090 |
Why?
|
Aldehyde Dehydrogenase | 1 | 2010 | 7 | 0.090 |
Why?
|
Receptors, Neurotensin | 1 | 2010 | 1 | 0.090 |
Why?
|
Genetic Testing | 1 | 2011 | 96 | 0.090 |
Why?
|
Neurotensin | 1 | 2010 | 4 | 0.090 |
Why?
|
beta Catenin | 1 | 2010 | 37 | 0.090 |
Why?
|
Cation Transport Proteins | 1 | 2010 | 24 | 0.090 |
Why?
|
Models, Statistical | 3 | 2006 | 173 | 0.090 |
Why?
|
Estrogens | 1 | 2011 | 180 | 0.090 |
Why?
|
Estrogen Receptor beta | 2 | 2007 | 13 | 0.090 |
Why?
|
Aged, 80 and over | 5 | 2018 | 3988 | 0.090 |
Why?
|
Camptothecin | 2 | 2017 | 51 | 0.090 |
Why?
|
rab GTP-Binding Proteins | 1 | 2009 | 4 | 0.090 |
Why?
|
Genes, erbB-2 | 1 | 2009 | 6 | 0.090 |
Why?
|
Data Interpretation, Statistical | 3 | 2008 | 109 | 0.080 |
Why?
|
Extracellular Signal-Regulated MAP Kinases | 1 | 2009 | 35 | 0.080 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p57 | 1 | 2009 | 1 | 0.080 |
Why?
|
Nerve Tissue Proteins | 1 | 2010 | 120 | 0.080 |
Why?
|
Comparative Genomic Hybridization | 1 | 2009 | 6 | 0.080 |
Why?
|
Carcinoma, Large Cell | 1 | 2009 | 4 | 0.080 |
Why?
|
Antineoplastic Agents | 1 | 2014 | 608 | 0.080 |
Why?
|
Chromosome Aberrations | 1 | 2009 | 23 | 0.080 |
Why?
|
Cells, Cultured | 3 | 2019 | 833 | 0.080 |
Why?
|
Receptor-Like Protein Tyrosine Phosphatases, Class 5 | 1 | 2008 | 1 | 0.080 |
Why?
|
Nasopharyngeal Neoplasms | 1 | 2008 | 5 | 0.080 |
Why?
|
Chromosomes, Human, Pair 13 | 1 | 2008 | 5 | 0.080 |
Why?
|
Thrombospondins | 1 | 2008 | 6 | 0.080 |
Why?
|
Feasibility Studies | 2 | 2019 | 293 | 0.080 |
Why?
|
Liver | 2 | 2013 | 484 | 0.080 |
Why?
|
Carcinoma | 1 | 2008 | 91 | 0.070 |
Why?
|
Genome, Viral | 2 | 2004 | 10 | 0.070 |
Why?
|
Protein Binding | 2 | 2019 | 201 | 0.070 |
Why?
|
Buchnera | 1 | 2007 | 1 | 0.070 |
Why?
|
Genome, Bacterial | 1 | 2007 | 6 | 0.070 |
Why?
|
Genes, cdc | 2 | 2008 | 5 | 0.070 |
Why?
|
Bacteriological Techniques | 1 | 2007 | 16 | 0.070 |
Why?
|
Arsenic | 1 | 2006 | 3 | 0.070 |
Why?
|
Cell Cycle | 4 | 2012 | 77 | 0.070 |
Why?
|
Databases, Genetic | 2 | 2005 | 37 | 0.070 |
Why?
|
Escherichia coli | 1 | 2007 | 87 | 0.070 |
Why?
|
Bacterial Infections | 1 | 2007 | 51 | 0.070 |
Why?
|
Selective Estrogen Receptor Modulators | 1 | 2006 | 36 | 0.070 |
Why?
|
Diagnosis, Computer-Assisted | 1 | 2007 | 53 | 0.070 |
Why?
|
Liver Neoplasms, Experimental | 1 | 2005 | 6 | 0.070 |
Why?
|
RNA, Messenger | 3 | 2016 | 508 | 0.070 |
Why?
|
Apoptosis | 3 | 2013 | 360 | 0.070 |
Why?
|
Pattern Recognition, Automated | 1 | 2006 | 33 | 0.070 |
Why?
|
Precancerous Conditions | 1 | 2005 | 27 | 0.060 |
Why?
|
Human Growth Hormone | 1 | 2005 | 4 | 0.060 |
Why?
|
Binding Sites | 4 | 2007 | 130 | 0.060 |
Why?
|
Xenograft Model Antitumor Assays | 2 | 2019 | 115 | 0.060 |
Why?
|
Gene Expression Regulation, Fungal | 1 | 2004 | 4 | 0.060 |
Why?
|
Schizosaccharomyces | 1 | 2004 | 5 | 0.060 |
Why?
|
Estrogen Replacement Therapy | 1 | 2006 | 199 | 0.060 |
Why?
|
Computer Simulation | 1 | 2006 | 220 | 0.060 |
Why?
|
Up-Regulation | 3 | 2012 | 189 | 0.060 |
Why?
|
Response Elements | 1 | 2004 | 16 | 0.060 |
Why?
|
Genes, Neoplasm | 1 | 2004 | 18 | 0.060 |
Why?
|
Cell Cycle Proteins | 1 | 2004 | 55 | 0.060 |
Why?
|
Regulatory Sequences, Nucleic Acid | 1 | 2004 | 24 | 0.060 |
Why?
|
Hyperthyroidism | 1 | 2004 | 2 | 0.060 |
Why?
|
Thyroid Hormone Receptors beta | 1 | 2004 | 2 | 0.060 |
Why?
|
Triiodothyronine | 1 | 2004 | 7 | 0.060 |
Why?
|
Cerebellum | 1 | 2004 | 26 | 0.060 |
Why?
|
Vero Cells | 1 | 2004 | 3 | 0.060 |
Why?
|
Genes | 1 | 2004 | 15 | 0.060 |
Why?
|
Mice, Inbred Strains | 1 | 2004 | 48 | 0.060 |
Why?
|
Risk Factors | 2 | 2016 | 3867 | 0.060 |
Why?
|
Base Composition | 1 | 2004 | 10 | 0.060 |
Why?
|
Consensus Sequence | 1 | 2004 | 10 | 0.060 |
Why?
|
Young Adult | 3 | 2018 | 2635 | 0.060 |
Why?
|
Base Pair Mismatch | 1 | 2004 | 6 | 0.060 |
Why?
|
Research Design | 2 | 2005 | 313 | 0.060 |
Why?
|
Nucleic Acid Hybridization | 1 | 2004 | 19 | 0.060 |
Why?
|
Molecular Sequence Data | 3 | 2011 | 359 | 0.060 |
Why?
|
Base Sequence | 3 | 2011 | 252 | 0.060 |
Why?
|
RNA, Viral | 1 | 2004 | 48 | 0.060 |
Why?
|
Sequence Analysis, RNA | 1 | 2004 | 28 | 0.060 |
Why?
|
Chromatin Immunoprecipitation | 3 | 2011 | 21 | 0.060 |
Why?
|
Occupational Diseases | 1 | 2004 | 81 | 0.060 |
Why?
|
Tissue Array Analysis | 2 | 2016 | 34 | 0.060 |
Why?
|
Myocardium | 1 | 2004 | 186 | 0.050 |
Why?
|
Intracellular Signaling Peptides and Proteins | 2 | 2015 | 73 | 0.050 |
Why?
|
Neoplasm Transplantation | 2 | 2013 | 73 | 0.050 |
Why?
|
Mice, Knockout | 1 | 2004 | 443 | 0.050 |
Why?
|
Quality Control | 1 | 2002 | 44 | 0.050 |
Why?
|
Cell Lineage | 1 | 2002 | 71 | 0.050 |
Why?
|
Cyclin E | 2 | 2012 | 5 | 0.050 |
Why?
|
Genes, Reporter | 2 | 2011 | 40 | 0.050 |
Why?
|
Follow-Up Studies | 2 | 2019 | 2265 | 0.050 |
Why?
|
DNA Damage | 1 | 2002 | 98 | 0.050 |
Why?
|
Mice, Inbred C57BL | 1 | 2004 | 767 | 0.050 |
Why?
|
Enzyme Inhibitors | 1 | 2002 | 166 | 0.050 |
Why?
|
Adipose Tissue | 1 | 2004 | 349 | 0.050 |
Why?
|
Loss of Heterozygosity | 2 | 2012 | 20 | 0.050 |
Why?
|
Time Factors | 1 | 2006 | 2147 | 0.050 |
Why?
|
Blotting, Western | 2 | 2011 | 289 | 0.050 |
Why?
|
Peritoneum | 1 | 2020 | 33 | 0.050 |
Why?
|
Immune System Phenomena | 1 | 2020 | 5 | 0.040 |
Why?
|
Tomography, X-Ray Computed | 2 | 2014 | 918 | 0.040 |
Why?
|
Cell Survival | 2 | 2010 | 284 | 0.040 |
Why?
|
Calcium Channel Blockers | 1 | 2019 | 48 | 0.040 |
Why?
|
Radiometry | 1 | 2019 | 40 | 0.040 |
Why?
|
Tumor Cells, Cultured | 2 | 2012 | 170 | 0.040 |
Why?
|
Lymph Nodes | 1 | 2019 | 107 | 0.040 |
Why?
|
Acrylamides | 1 | 2018 | 4 | 0.040 |
Why?
|
Hydroxamic Acids | 2 | 2009 | 21 | 0.040 |
Why?
|
Nicotinamide Phosphoribosyltransferase | 1 | 2018 | 13 | 0.040 |
Why?
|
Protein Kinases | 1 | 2018 | 26 | 0.040 |
Why?
|
Tretinoin | 1 | 2018 | 34 | 0.040 |
Why?
|
Cell Respiration | 1 | 2018 | 22 | 0.040 |
Why?
|
Mitoxantrone | 1 | 2018 | 19 | 0.040 |
Why?
|
Metaplasia | 1 | 2018 | 19 | 0.040 |
Why?
|
Retreatment | 1 | 2018 | 41 | 0.040 |
Why?
|
Cytarabine | 1 | 2018 | 55 | 0.040 |
Why?
|
Pilot Projects | 1 | 2019 | 545 | 0.040 |
Why?
|
Carcinoma, Ductal, Breast | 1 | 2018 | 30 | 0.040 |
Why?
|
Fatty Acids | 1 | 2018 | 98 | 0.040 |
Why?
|
Pathology, Molecular | 1 | 2017 | 16 | 0.040 |
Why?
|
Bone Marrow | 1 | 2018 | 70 | 0.040 |
Why?
|
Piperidines | 1 | 2018 | 118 | 0.040 |
Why?
|
Lymphopenia | 1 | 2017 | 11 | 0.040 |
Why?
|
Hypokalemia | 1 | 2017 | 13 | 0.040 |
Why?
|
Leucovorin | 1 | 2017 | 24 | 0.040 |
Why?
|
Neutropenia | 1 | 2017 | 29 | 0.040 |
Why?
|
Hypoalbuminemia | 1 | 2017 | 11 | 0.040 |
Why?
|
Sensation Disorders | 1 | 2017 | 19 | 0.040 |
Why?
|
Thrombocytopenia | 1 | 2017 | 30 | 0.040 |
Why?
|
Maximum Tolerated Dose | 1 | 2017 | 62 | 0.040 |
Why?
|
Prospective Studies | 2 | 2019 | 2278 | 0.040 |
Why?
|
Organoplatinum Compounds | 1 | 2017 | 46 | 0.040 |
Why?
|
Oxygen Consumption | 1 | 2018 | 154 | 0.040 |
Why?
|
Abdominal Pain | 1 | 2017 | 44 | 0.040 |
Why?
|
Lipids | 1 | 2018 | 232 | 0.040 |
Why?
|
Anemia | 1 | 2017 | 58 | 0.040 |
Why?
|
Fluorouracil | 1 | 2017 | 81 | 0.040 |
Why?
|
Cytokines | 1 | 2018 | 255 | 0.040 |
Why?
|
B-Lymphocytes | 1 | 2017 | 74 | 0.040 |
Why?
|
Biopsy | 1 | 2018 | 259 | 0.040 |
Why?
|
Hyperglycemia | 1 | 2017 | 84 | 0.030 |
Why?
|
Phytoestrogens | 1 | 2016 | 23 | 0.030 |
Why?
|
Bayes Theorem | 1 | 2016 | 80 | 0.030 |
Why?
|
Gene Knockout Techniques | 1 | 2015 | 11 | 0.030 |
Why?
|
Structure-Activity Relationship | 1 | 2016 | 80 | 0.030 |
Why?
|
Protein Transport | 1 | 2015 | 74 | 0.030 |
Why?
|
DNA Modification Methylases | 1 | 2015 | 11 | 0.030 |
Why?
|
DNA Repair Enzymes | 1 | 2015 | 14 | 0.030 |
Why?
|
Sepsis | 1 | 2017 | 158 | 0.030 |
Why?
|
Dose-Response Relationship, Radiation | 1 | 2015 | 81 | 0.030 |
Why?
|
Species Specificity | 2 | 2005 | 90 | 0.030 |
Why?
|
African Continental Ancestry Group | 1 | 2016 | 363 | 0.030 |
Why?
|
Radiotherapy | 1 | 2015 | 82 | 0.030 |
Why?
|
Salvage Therapy | 1 | 2015 | 134 | 0.030 |
Why?
|
MAP Kinase Kinase Kinases | 1 | 2014 | 4 | 0.030 |
Why?
|
I-kappa B Kinase | 1 | 2014 | 8 | 0.030 |
Why?
|
Prostate | 1 | 2015 | 68 | 0.030 |
Why?
|
Matrix Metalloproteinase 9 | 1 | 2014 | 30 | 0.030 |
Why?
|
Macaca fascicularis | 1 | 2016 | 434 | 0.030 |
Why?
|
Leukemia | 1 | 2014 | 40 | 0.030 |
Why?
|
Apoferritins | 1 | 2013 | 4 | 0.030 |
Why?
|
Receptors, Transferrin | 1 | 2013 | 10 | 0.030 |
Why?
|
Databases, Factual | 1 | 2015 | 351 | 0.030 |
Why?
|
Clinical Trials as Topic | 1 | 2016 | 301 | 0.030 |
Why?
|
Drug Administration Schedule | 1 | 2014 | 276 | 0.030 |
Why?
|
Mammary Neoplasms, Experimental | 1 | 2013 | 29 | 0.030 |
Why?
|
G2 Phase | 2 | 2004 | 17 | 0.030 |
Why?
|
Cell Differentiation | 1 | 2016 | 469 | 0.030 |
Why?
|
Diet | 1 | 2016 | 391 | 0.030 |
Why?
|
Antigens, CD | 1 | 2013 | 103 | 0.030 |
Why?
|
Positron-Emission Tomography | 1 | 2014 | 163 | 0.030 |
Why?
|
Practice Guidelines as Topic | 1 | 2016 | 407 | 0.030 |
Why?
|
Cyclin D1 | 1 | 2013 | 14 | 0.030 |
Why?
|
Cyclin D2 | 1 | 2013 | 7 | 0.030 |
Why?
|
Mice, SCID | 1 | 2013 | 71 | 0.030 |
Why?
|
Internet | 2 | 2004 | 195 | 0.030 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2012 | 22 | 0.030 |
Why?
|
European Continental Ancestry Group | 1 | 2017 | 1166 | 0.030 |
Why?
|
Oncogene Proteins | 1 | 2012 | 6 | 0.030 |
Why?
|
Cell Shape | 1 | 2012 | 28 | 0.030 |
Why?
|
Cations, Monovalent | 1 | 2011 | 1 | 0.030 |
Why?
|
DNA Footprinting | 1 | 2011 | 1 | 0.030 |
Why?
|
GC Rich Sequence | 1 | 2011 | 1 | 0.030 |
Why?
|
Circular Dichroism | 1 | 2011 | 30 | 0.020 |
Why?
|
Protein Kinase Inhibitors | 1 | 2012 | 85 | 0.020 |
Why?
|
Oligodeoxyribonucleotides | 1 | 2011 | 17 | 0.020 |
Why?
|
Protein Processing, Post-Translational | 1 | 2012 | 78 | 0.020 |
Why?
|
Trypsin Inhibitor, Kazal Pancreatic | 1 | 2011 | 1 | 0.020 |
Why?
|
Far East | 1 | 2011 | 3 | 0.020 |
Why?
|
Chromosomes, Human, Pair 19 | 1 | 2011 | 13 | 0.020 |
Why?
|
DNA Copy Number Variations | 1 | 2011 | 13 | 0.020 |
Why?
|
Chromosomes, Human, Pair 16 | 1 | 2011 | 15 | 0.020 |
Why?
|
Prevalence | 1 | 2014 | 981 | 0.020 |
Why?
|
Europe | 1 | 2011 | 82 | 0.020 |
Why?
|
RNA | 1 | 2011 | 92 | 0.020 |
Why?
|
Bone Morphogenetic Protein 2 | 1 | 2010 | 20 | 0.020 |
Why?
|
Retinal Dehydrogenase | 1 | 2010 | 2 | 0.020 |
Why?
|
Mammary Glands, Human | 1 | 2010 | 15 | 0.020 |
Why?
|
Antimicrobial Cationic Peptides | 1 | 2010 | 14 | 0.020 |
Why?
|
Antibodies | 1 | 2010 | 52 | 0.020 |
Why?
|
Neoplasms, Experimental | 1 | 2010 | 29 | 0.020 |
Why?
|
Linear Models | 1 | 2011 | 447 | 0.020 |
Why?
|
Cell Adhesion | 1 | 2010 | 108 | 0.020 |
Why?
|
Cisplatin | 1 | 2010 | 76 | 0.020 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 1 | 2010 | 34 | 0.020 |
Why?
|
Recombinant Proteins | 1 | 2010 | 247 | 0.020 |
Why?
|
Receptor Cross-Talk | 1 | 2009 | 3 | 0.020 |
Why?
|
African Americans | 1 | 2017 | 1425 | 0.020 |
Why?
|
Breast | 1 | 2010 | 68 | 0.020 |
Why?
|
Expressed Sequence Tags | 1 | 2009 | 2 | 0.020 |
Why?
|
Sex Factors | 1 | 2011 | 661 | 0.020 |
Why?
|
Chromosomes, Human, Pair 3 | 1 | 2008 | 28 | 0.020 |
Why?
|
Multivariate Analysis | 1 | 2010 | 683 | 0.020 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2009 | 210 | 0.020 |
Why?
|
Artifacts | 1 | 2008 | 39 | 0.020 |
Why?
|
Chromosome Segregation | 1 | 2008 | 3 | 0.020 |
Why?
|
Cell Line, Transformed | 1 | 2008 | 18 | 0.020 |
Why?
|
Tumor Stem Cell Assay | 1 | 2008 | 12 | 0.020 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2008 | 40 | 0.020 |
Why?
|
Microsatellite Repeats | 1 | 2008 | 21 | 0.020 |
Why?
|
Epithelium | 1 | 2008 | 30 | 0.020 |
Why?
|
Magnetic Resonance Imaging | 1 | 2014 | 1328 | 0.020 |
Why?
|
Deoxycytidine | 1 | 2008 | 68 | 0.020 |
Why?
|
Alleles | 1 | 2008 | 248 | 0.020 |
Why?
|
E2F Transcription Factors | 1 | 2007 | 1 | 0.020 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2011 | 1062 | 0.020 |
Why?
|
Multigene Family | 1 | 2007 | 51 | 0.020 |
Why?
|
Metabolic Networks and Pathways | 1 | 2006 | 19 | 0.020 |
Why?
|
Premenopause | 1 | 2006 | 44 | 0.020 |
Why?
|
Adaptation, Physiological | 1 | 2006 | 55 | 0.020 |
Why?
|
HCT116 Cells | 1 | 2006 | 11 | 0.020 |
Why?
|
Conserved Sequence | 1 | 2005 | 20 | 0.020 |
Why?
|
Adolescent | 1 | 2014 | 3537 | 0.020 |
Why?
|
Sequence Homology, Amino Acid | 1 | 2005 | 70 | 0.020 |
Why?
|
Carcinogens | 1 | 2005 | 35 | 0.020 |
Why?
|
RNA Probes | 1 | 2005 | 4 | 0.020 |
Why?
|
DNA Probes | 1 | 2005 | 19 | 0.020 |
Why?
|
Mucins | 1 | 2005 | 18 | 0.020 |
Why?
|
Amino Acid Sequence | 1 | 2005 | 285 | 0.020 |
Why?
|
Genome, Fungal | 1 | 2004 | 1 | 0.020 |
Why?
|
ras-GRF1 | 1 | 2004 | 1 | 0.020 |
Why?
|
G1 Phase | 1 | 2004 | 11 | 0.020 |
Why?
|
Fungal Proteins | 1 | 2004 | 7 | 0.020 |
Why?
|
DNA, Complementary | 1 | 2004 | 30 | 0.020 |
Why?
|
Normal Distribution | 1 | 2004 | 12 | 0.020 |
Why?
|
Amino Acid Motifs | 1 | 2004 | 24 | 0.020 |
Why?
|
S Phase | 1 | 2004 | 15 | 0.020 |
Why?
|
Muscle Proteins | 1 | 2005 | 59 | 0.020 |
Why?
|
Saccharomyces cerevisiae | 1 | 2004 | 20 | 0.020 |
Why?
|
Oligonucleotides | 1 | 2005 | 30 | 0.020 |
Why?
|
Temperature | 1 | 2004 | 55 | 0.020 |
Why?
|
Software Design | 1 | 2004 | 6 | 0.020 |
Why?
|
Genome | 1 | 2004 | 38 | 0.020 |
Why?
|
Chromatin | 1 | 2004 | 25 | 0.020 |
Why?
|
Singapore | 1 | 2004 | 10 | 0.010 |
Why?
|
Cell Separation | 1 | 2004 | 92 | 0.010 |
Why?
|
Laboratories | 1 | 2004 | 15 | 0.010 |
Why?
|
Flow Cytometry | 1 | 2004 | 185 | 0.010 |
Why?
|
DNA, Neoplasm | 1 | 2004 | 55 | 0.010 |
Why?
|
Phylogeny | 1 | 2004 | 56 | 0.010 |
Why?
|
Postmenopause | 1 | 2006 | 430 | 0.010 |
Why?
|
Cell Nucleus | 1 | 2004 | 108 | 0.010 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2006 | 367 | 0.010 |
Why?
|
Genotype | 1 | 2004 | 733 | 0.010 |
Why?
|
Biomedical Research | 1 | 2004 | 156 | 0.010 |
Why?
|
Aphidicolin | 1 | 2002 | 1 | 0.010 |
Why?
|
Mitosis | 1 | 2002 | 25 | 0.010 |
Why?
|
Biopsy, Needle | 1 | 2002 | 93 | 0.010 |
Why?
|
Colonic Neoplasms | 1 | 2002 | 71 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2002 | 632 | 0.010 |
Why?
|